Madrigal Q1 Rezdiffra net sales $311.3M (+127% YoY); pipeline expanded with siRNA deal

MADRIGAL PHARMACEUTICALS, INC.

2026-Q1 EPS reported -$3.25 revenue$311,337,000

Q1 2026 Rezdiffra net sales $311.3M, up 127% YoY from $137.3M; over 42,250 patients on therapy, 2.5x vs Q1 2025.
Licensed ARO-PNPLA3 from Arrowhead; clinical-stage siRNA targeting PNPLA3 mutation in MASH (≈30% of F2/F3 patients).
Net loss $94.4M ($3.25/share) vs $73.2M ($2.61) prior year; includes $54.3M one-time upfront BD expenses.
Cash $817.9M at Mar 31 (down from $988.6M Dec 31); MGL-2086 Phase 1 on track for Q2 2026.
Operating expenses $404.1M (incl $34M stock comp) vs $216.6M; SG&A up due to commercial investment.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

MADRIGAL PHARMACEUTICALS, INC. reported the quarter ended March 31, 2026 results: revenue $311.3 million, net income ($94.4 million) or ($3.25) per share (basic and diluted), EPS ($3.25).

Period: the quarter ended March 31, 2026
Revenue: $311.3 million
Net income: ($94.4 million) or ($3.25) per share (basic and diluted)
EPS: ($3.25)
Result: reported results

Exact text from the filing

(EX-99.1) --- Madrigal Pharmaceuticals Reports First -Quarter 2026 Financial Results and Provides Corporate Updates • First-quarter 2026 Rezdiffra ® (resmetirom) net sales of $311.3 million, representing year-over-year growth of 127% • As of March 31, 2026, more than 42,250 patients on Rezdiffra, up 2.5x from 1Q25, reflecting continued strong physician adoption and

View on SEC.gov

Browse all earnings releases →

MADRIGAL PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001628280-26-030896

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.